T
Thomas Foltynie
Researcher at UCL Institute of Neurology
Publications - 381
Citations - 26959
Thomas Foltynie is an academic researcher from UCL Institute of Neurology. The author has contributed to research in topics: Deep brain stimulation & Parkinson's disease. The author has an hindex of 80, co-authored 352 publications receiving 21023 citations. Previous affiliations of Thomas Foltynie include University College London & University of Kent.
Papers
More filters
Journal ArticleDOI
Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis.
Dag Aarsland,Kolbjørn Brønnick,Caroline H. Williams-Gray,Daniel Weintraub,Karen Marder,Jaime Kulisevsky,David J. Burn,Paolo Barone,J. Pagonabarraga,Liesl M. Allcock,Gabriella Santangelo,Thomas Foltynie,Carmen Janvin,Jan Petter Larsen,Roger A. Barker,Murat Emre +15 more
TL;DR: Having MCI was associated with older age at assessment and at disease onset, male gender, depression, more severe motor symptoms, and advanced disease stage, and future studies of patients with PD with MCI need to determine risk factors for ongoing cognitive decline and assess interventions at a predementia stage.
Journal ArticleDOI
Heterogeneity of Parkinson’s disease in the early clinical stages using a data driven approach
Simon J.G. Lewis,Thomas Foltynie,Andrew D. Blackwell,Trevor W. Robbins,Adrian M. Owen,Roger A. Barker +5 more
TL;DR: The approach adopted in this study for the identification of subgroups of patients within Parkinson’s disease has important implications for generating testable hypotheses on defining the heterogeneity of this common condition and its aetiopathological basis and thus its treatment.
Journal ArticleDOI
The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort
Caroline H. Williams-Gray,Sarah L Mason,Jonathan R. Evans,Thomas Foltynie,Carol Brayne,Trevor W. Robbins,Roger A. Barker +6 more
TL;DR: The CamPaIGN study as mentioned in this paper has been the first to prospectively track disease evolution from diagnosis in an unselected population-representative incident cohort, focusing on three key irreversible milestones: postural instability (Hoehn and Yahr 3), dementia and death.
Journal ArticleDOI
Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial
Dilan Athauda,Kate Maclagan,Simon S. Skene,Martha Bajwa-Joseph,Dawn Letchford,Kashfia Chowdhury,Steve Hibbert,Natalia Budnik,Luca Zampedri,John Dickson,Yazhou Li,Iciar Aviles-Olmos,Thomas T. Warner,Patricia Limousin,Andrew J. Lees,Nigel H. Greig,Susan Tebbs,Thomas Foltynie +17 more
TL;DR: Exenatide had positive effects on practically defined off-medication motor scores in Parkinson's disease, which were sustained beyond the period of exposure.
Journal ArticleDOI
Resting oscillatory cortico-subthalamic connectivity in patients with Parkinson's disease
Vladimir Litvak,Vladimir Litvak,Ashwani Jha,Ashwani Jha,Alexandre Eusebio,Robert Oostenveld,Thomas Foltynie,Patricia Limousin,Ludvic Zrinzo,Marwan Hariz,Karl J. Friston,Peter Brown +11 more
TL;DR: A newly described, electrophysiological method is used to describe cortico-subthalamic networks in humans and it is suggested that these networks may be involved in attentional and executive, particularly motor planning, processes, respectively.